For the year ending 2025-12-31, PRTA had -$163,857K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -244,092 |
| Depreciation | 895 |
| Share-based compensation | 37,640 |
| Deferred income taxes | 43,239 |
| Reduction in the carrying amount of right-of-use assets | 2,807 |
| Loss on disposal of fixed assets | -104 |
| Accounts receivable | 0 |
| Prepaid expenses and other assets | -10,628 |
| Deferred revenue | -9,634 |
| Restructuring liability | 13,303 |
| Accounts payable, accruals and other liabilities | -15,776 |
| Operating lease liabilities | -2,694 |
| Net cash used in operating activities | -163,580 |
| Purchases of property and equipment | 138 |
| Proceeds from disposal of fixed assets | 0 |
| Net cash used in investing activities | -138 |
| Proceeds from issuance of ordinary shares in public offering, net-Public Offering | 0 |
| Proceeds from issuance of ordinary shares in at-the market offering, net-At The Market Offering | -139 |
| Proceeds from issuance of ordinary shares upon exercise of stock options | 0 |
| Net cash provided by (used in) financing activities | -139 |
| Net decrease in cash, cash equivalents and restricted cash | -163,857 |
| Cash, cash equivalents and restricted cash, beginning of the year | 472,248 |
| Cash, cash equivalents and restricted cash, end of the year | 308,391 |
PROTHENA CORP PUBLIC LTD CO (PRTA)
PROTHENA CORP PUBLIC LTD CO (PRTA)